IR News
This document provides integrated information to the media. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
-
R&DGivinostat Update script
-
R&DGivinostat Update Material
-
R&DJCR Pharmaceuticals Announces Development Plan in Japan for Givinostat for Duchenne Muscular DystrophyView PDF
-
FinancesPartial Correction: Consolidated Financial Results for the Full Year ended March 31, 2026 (FY2025) (Japanese standard)
-
FinancesPartial Correction: Consolidated Financial Results for the Full Year ended March 31, 2025 (FY2024) (Japanese standard)
-
LicensingJCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform
-
R&DJCR Pharmaceuticals’ Research Presentations at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026
-
CorporateOther Matters Subject to Measures for Electronic Provision When Convening the 51st Ordinary General Meeting of Shareholders
-
CorporateNotice of Convocation of The 51st Ordinary General Meeting of Shareholders
-
R&DJCR Pharmaceuticals to Present at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026